SCHEMBL4456152

SCHEMBL4456152

COCCn1cccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12524569 0.84 ALDH1A1 (0.41)
SCHEMBL15216191 0.82 ALDH1A1 (0.36)
SCHEMBL5032553 0.80 TP53 (0.33)
SCHEMBL8050553 0.74 ALDH1A1 (0.36)
SCHEMBL13141017 0.72
SCHEMBL26860487 0.72
SCHEMBL12304188 0.72 TP53 (0.34)
SCHEMBL28035357 0.72 KDM4E (0.38)
SCHEMBL30301314 0.72 ALDH1A1 (0.35)
SCHEMBL1149306 0.72 TP53 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109897054-A The preparation method and its usage of triazolothiadiazole c-Met kinase inhibitor 中国药科大学 2019-06-18 CN claimed
CN-105980386-A Pyrazolo compounds and uses thereof 基因泰克公司 2016-09-28 CN claimed
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP claimed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US claimed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO claimed
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 US disclosed
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds PMV PHARMACEUTICALS, INC. (US) 2025-09-23 US disclosed
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. 2024-08-15 US disclosed
US-11938124-B2 Combination therapy for treatment of cancer PMV PHARMACEUTICALS, INC. (US) 2024-03-26 US disclosed
US-20230049952-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 US disclosed
US-20230044826-A1 COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS PMV PHARMACEUTICALS, INC. 2023-02-09 US disclosed
WO-2000058373-A1 PROCESS FOR PRODUCING POLYOLEFINS EASTMAN CHEMICAL COMPANY (US) 2000-10-05 WO disclosed
WO-2000058372-A1 PROCESS FOR PRODUCING POLYOLEFINS EASTMAN CHEMICAL COMPANY (US) 2000-10-05 WO disclosed
WO-2000058371-A1 PROCESS FOR PRODUCING POLYOLEFINS EASTMAN CHEMICAL COMPANY (US) 2000-10-05 WO disclosed
WO-2000052069-A1 PROCESS FOR PRODUCING POLYETHYLENE EASTMAN CHEMICAL COMPANY (US) 2000-09-08 WO disclosed
WO-2000052068-A1 PROCESS FOR PRODUCING POLYETHYLENE EASTMAN CHEMICAL COMPANY (US) 2000-09-08 WO disclosed
WO-2000052067-A1 PROCESS FOR PRODUCING POLYETHYLENE EASTMAN CHEMICAL COMPANY (US) 2000-09-08 WO disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed
US-3980089-A Novel heterocyclic flavoring compositions and processes INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1976-09-14 US disclosed